Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Kassis (2004)
The Amazing World of Auger ElectronsInternational Journal of Radiation Biology, 80
K. Sugahara, T. Teesalu, P. Karmali, V. Kotamraju, L. Agemy, O. Girard, D. Hanahan, R. Mattrey, E. Ruoslahti (2009)
Tissue-penetrating delivery of compounds and nanoparticles into tumors.Cancer cell, 16 6
C. Kue, A. Kamkaew, K. Burgess, L. Kiew, L. Chung, Hong-Boon Lee (2016)
Small Molecules for Active Targeting in CancerMedicinal Research Reviews, 36
H. Michiue, Y. Sakurai, N. Kondo, Mizuki Kitamatsu, Feng Bin, K. Nakajima, Y. Hirota, S. Kawabata, T. Nishiki, I. Ohmori, K. Tomizawa, S. Miyatake, K. Ono, H. Matsui (2014)
The acceleration of boron neutron capture therapy using multi-linked mercaptoundecahydrododecaborate (BSH) fused cell-penetrating peptide.Biomaterials, 35 10
Weilian Yang, R. Barth, Gong Wu, W. Tjarks, P. Binns, K. Riley (2009)
Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents.Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 67 7-8 Suppl
D. Zwanziger, Ilka Böhme, D. Lindner, A. Beck‐Sickinger (2009)
First selective agonist of the neuropeptide Y1‐receptor with reduced sizeJournal of Peptide Science, 15
Y. Miao, N. Owen, D. Fisher, T. Hoffman, T. Quinn (2004)
-Melanocyte–Stimulating Hormone Peptide Analog in Murine and Human Melanoma-Bearing Mouse Models
M. Michel, A. Beck‐Sickinger, H. Cox, H. Doods, Herbert Herzog, D. Larhammar, R. Quirion, T. Schwartz, T. Westfall (1998)
XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors.Pharmacological reviews, 50 1
Su-Eon Jin, Hyo-Eon Jin, Soon-Sun Hong (2014)
Targeted Delivery System of Nanobiomaterials in Anticancer Therapy: From Cells to ClinicsBioMed Research International, 2014
K. Mörl, A. Beck‐Sickinger (2015)
Intracellular Trafficking of Neuropeptide Y Receptors.Progress in molecular biology and translational science, 132
E. Plow, T. Haas, Li Zhang, J. Loftus, Jeffrey Smith (2000)
Ligand Binding to Integrins*The Journal of Biological Chemistry, 275
Shin Cha, H. Gu, Ki Lee, Mun Lee, S. Han, Tae Jeong (2000)
Immunotoxicity of ethyl carbamate in female BALB/c mice: role of esterase and cytochrome P450.Toxicology letters, 115 3
S. Kawabata, S. Miyatake, N. Nonoguchi, R. Hiramatsu, Kyoko Iida, S. Miyata, K. Yokoyama, Atsushi Doi, Yuzo Kuroda, T. Kuroiwa, H. Michiue, H. Kumada, M. Kirihata, Y. Imahori, A. Maruhashi, Y. Sakurai, Minoru Suzuki, S. Masunaga, K. Ono (2009)
Survival benefit from boron neutron capture therapy for the newly diagnosed glioblastoma patients.Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 67 7-8 Suppl
C. Huang, Y. Wu, S. Chen (2000)
Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis.Chemistry & biology, 7 7
A. Soloway, H. Hatanaka, M. Davis (1967)
Penetration of brain and brain tumor. VII. Tumor-binding sulfhydryl boron compounds.Journal of medicinal chemistry, 10 4
Y. Yarden, Gur Pines (2012)
The ERBB network: at last, cancer therapy meets systems biologyNature Reviews Cancer, 12
J. Reubi (2003)
Peptide receptors as molecular targets for cancer diagnosis and therapy.Endocrine reviews, 24 4
Weilian Yang, R. Barth, Gong Wu, S. Kawabata, T. Sferra, A. Bandyopadhyaya, W. Tjarks, A. Ferketich, M. Moeschberger, P. Binns, K. Riley, J. Coderre, M. Ciesielski, R. Fenstermaker, C. Wikstrand (2006)
Molecular Targeting and Treatment of EGFRvIII-Positive Gliomas Using Boronated Monoclonal Antibody L8A4Clinical Cancer Research, 12
Eirinaios Vrettos, G. Mező, A. Tzakos (2018)
On the design principles of peptide–drug conjugates for targeted drug delivery to the malignant tumor siteBeilstein Journal of Organic Chemistry, 14
Huanli Sun, Yangyang Dong, J. Feijen, Z. Zhong (2018)
Peptide‐decorated polymeric nanomedicines for precision cancer therapyJournal of Controlled Release, 290
Y. Kato, S. Ozawa, C. Miyamoto, Y. Maehata, Atsuko Suzuki, T. Maeda, Y. Baba (2013)
Acidic extracellular microenvironment and cancerCancer Cell International, 13
P. Laverman, Lieke Joosten, A. Eek, S. Roosenburg, P. Peitl, T. Maina, H. Mäcke, L. Aloj, E. Guggenberg, J. Sosabowski, M. Jong, J. Reubi, W. Oyen, O. Boerman (2011)
Comparative biodistribution of 12 111In-labelled gastrin/CCK2 receptor-targeting peptidesEuropean Journal of Nuclear Medicine and Molecular Imaging, 38
R. Nargund, A. Patchett, M. Bach, M. Murphy, R. Smith (1998)
Peptidomimetic growth hormone secretagogues. Design considerations and therapeutic potential.Journal of medicinal chemistry, 41 17
Roy Smith, L. Ploeg, A. Howard, S. Feighner, K. Cheng, G. Hickey, M. Wyvratt, M. Fisher, R. Nargund, A. Patchett (1997)
Peptidomimetic regulation of growth hormone secretion.Endocrine reviews, 18 5
G. Hodges, D. Jackson, L. Mattar, John Johnson, J. Shoemaker (2009)
Neuropeptide Y and neurovascular control in skeletal muscle and skin.American journal of physiology. Regulatory, integrative and comparative physiology, 297 3
Veronika Mäde, Sylvia Els‐Heindl, A. Beck‐Sickinger (2014)
Automated solid-phase peptide synthesis to obtain therapeutic peptidesBeilstein Journal of Organic Chemistry, 10
A. Ciechanover (2005)
Intracellular protein degradation: from a vague idea, through the lysosome and the ubiquitin-proteasome system, and onto human diseases and drug targeting (Nobel lecture).Angewandte Chemie, 44 37
Boris Redko, E. Ragozin, Bazylevich Andreii, Tuchinsky Helena, Albeck Amnon, Shekhter Talia, O. Mor, Kostenich Genady, Geller Gary (2015)
Synthesis, drug release, and biological evaluation of new anticancer drug–bioconjugates containing somatostatin backbone cyclic analog as a targeting moietyPeptide Science, 104
G. Saito, J. Swanson, Kyung-Dall Lee (2003)
Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities.Advanced drug delivery reviews, 55 2
S. Masunaga, Sadaaki Kimura, Tomohiro Harada, K. Okuda, Y. Sakurai, Hiroki Tanaka, Minoru Suzuki, N. Kondo, A. Maruhashi, H. Nagasawa, K. Ono (2012)
Evaluating the Usefulness of a Novel 10B-Carrier Conjugated With Cyclic RGD Peptide in Boron Neutron Capture TherapyWorld Journal of Oncology, 3
M. Fani, P. Peitl, I. Velikyan (2017)
Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine NeoplasmsPharmaceuticals, 10
T. Hartman, J. Carlsson (1994)
Radiation dose heterogeneity in receptor and antigen mediated boron neutron capture therapy.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 31 1
R. Jensen, J. Battey, E. Spindel, R. Benya (2008)
Mammalian Bombesin Receptors : Nomenclature , Distribution , Pharmacology , Signaling , and Functions in Normal and Disease States
Y. Mori, A. Suzuki, K. Yoshino, H. Kakihana (1989)
Complex formation of p-boronophenylalanine with some monosaccharides.Pigment cell research, 2 4
S. Monks, Gloria Karagianis, G. Howlett, R. Norton (1996)
Solution structure of human neuropeptide YJournal of Biomolecular NMR, 8
V. Sancho, A. Florio, T. Moody, R. Jensen (2011)
Bombesin receptor-mediated imaging and cytotoxicity: review and current status.Current drug delivery, 8 1
R. Barth, Zizhu Zhang, Tong Liu (2018)
A realistic appraisal of boron neutron capture therapy as a cancer treatment modalityCancer Communications, 38
N. Holliday, B. Holst, Elena Rodionova, T. Schwartz, H. Cox (2007)
Importance of constitutive activity and arrestin-independent mechanisms for intracellular trafficking of the ghrelin receptor.Molecular endocrinology, 21 12
Rózsa Hegedüs, M. Manea, E. Orbán, I. Szabó, É. Kiss, É. Sipos, G. Halmos, G. Mező (2012)
Enhanced cellular uptake and in vitro antitumor activity of short-chain fatty acid acylated daunorubicin-GnRH-III bioconjugates.European journal of medicinal chemistry, 56
Gong Wu, Weilian Yang, R. Barth, S. Kawabata, Michele Swindall, A. Bandyopadhyaya, W. Tjarks, B. Khorsandi, T. Blue, A. Ferketich, Ming Yang, G. Christoforidis, T. Sferra, P. Binns, K. Riley, M. Ciesielski, R. Fenstermaker (2007)
Molecular Targeting and Treatment of an Epidermal Growth Factor Receptor–Positive Glioma Using Boronated CetuximabClinical Cancer Research, 13
Feng-Ling Tukun, D. Olberg, P. Riss, Ira Haraldsen, Anita Kaass, J. Klaveness (2017)
Recent Development of Non-Peptide GnRH AntagonistsMolecules : A Journal of Synthetic Chemistry and Natural Product Chemistry, 22
T. Moody, Li-chun Sun, S. Mantey, T. Pradhan, L. Mackey, Nieves Gonzales, J. Fuselier, D. Coy, R. Jensen (2006)
In Vitro and in Vivo Antitumor Effects of Cytotoxic Camptothecin-Bombesin Conjugates Are Mediated by Specific Interaction with Cellular Bombesin ReceptorsJournal of Pharmacology and Experimental Therapeutics, 318
Yuxiang Sun, Pei Wang, Hui Zheng, Roy Smith (2004)
Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor.Proceedings of the National Academy of Sciences of the United States of America, 101 13
Xiaolian Sun, Yesen Li, Ting Liu, Zijing Li, Xianzhong Zhang, Xiaoyuan Chen (2017)
Peptide‐based imaging agents for cancer detectionAdvanced Drug Delivery Reviews, 110‐111
M. Riaz, Muhammad Riaz, Xue Zhang, Congcong Lin, Ka Wong, Xiaoyu Chen, Ge Zhang, Aiping Lu, Zhijun Yang (2018)
Surface Functionalization and Targeting Strategies of Liposomes in Solid Tumor Therapy: A ReviewInternational Journal of Molecular Sciences, 19
R. Hynes (1987)
Integrins: A family of cell surface receptorsCell, 48
C. Galmarini, J. Mackey, C. Dumontet (2002)
Nucleoside analogues and nucleobases in cancer treatment.The Lancet. Oncology, 3 7
Hervé Gicquiaux, S. Lecat, M. Gaire, A. Dieterlen, Y. Mély, K. Takeda, B. Bucher, J. Galzi (2002)
Rapid Internalization and Recycling of the Human Neuropeptide Y Y1 Receptor*The Journal of Biological Chemistry, 277
Yoshiya Iguchi, H. Michiue, Mizuki Kitamatsu, Yuri Hayashi, Fumiaki Takenaka, T. Nishiki, H. Matsui (2015)
Tumor-specific delivery of BSH-3R for boron neutron capture therapy and positron emission tomography imaging in a mouse brain tumor model.Biomaterials, 56
Xavier Pedragosa-Badia, Jan Stichel, A. Beck‐Sickinger (2013)
Neuropeptide Y receptors: how to get subtype selectivityFrontiers in Endocrinology, 4
Martin Kellert, Dennis Worm, Paul Hoppenz, M. Sárosi, P. Lönnecke, B. Riedl, J. Koebberling, A. Beck‐Sickinger, E. Hey‐Hawkins (2019)
Modular triazine-based carborane-containing carboxylic acids - synthesis and characterisation of potential boron neutron capture therapy agents made of readily accessible building blocks.Dalton transactions
Miloš Erak, K. Bellmann-Sickert, Sylvia Els‐Heindl, A. Beck‐Sickinger (2018)
Peptide chemistry toolbox - Transforming natural peptides into peptide therapeutics.Bioorganic & medicinal chemistry, 26 10
J. Reubi, J. Schär, B. Waser, S. Wenger, A. Heppeler, J. Schmitt, H. Mäcke (2000)
Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic useEuropean Journal of Nuclear Medicine, 27
Anna Szlachcic, M. Zakrzewska, Michal Lobocki, P. Jakimowicz, J. Otlewski (2016)
Design and characteristics of cytotoxic fibroblast growth factor 1 conjugate for fibroblast growth factor receptor-targeted cancer therapyDrug Design, Development and Therapy, 10
M. Schottelius, H. Wester (2009)
Molecular imaging targeting peptide receptors.Methods, 48 2
T. Moody, S. Mantey, J. Fuselier, D. Coy, R. Jensen (2007)
Vasoactive intestinal peptide–camptothecin conjugates inhibit the proliferation of breast cancer cellsPeptides, 28
G. Harrison, M. Wierman, T. Nett, L. Glodé (2004)
Gonadotropin-releasing hormone and its receptor in normal and malignant cells.Endocrine-related cancer, 11 4
L. Bildstein, C. Dubernet, P. Couvreur (2011)
Prodrug-based intracellular delivery of anticancer agents.Advanced drug delivery reviews, 63 1-2
D. Rosenbaum, S. Rasmussen, B. Kobilka (2009)
The structure and function of G-protein-coupled receptorsNature, 459
Shuang Liu, D. Edwards (2001)
Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals.Bioconjugate chemistry, 12 1
C. Moore, S. Milano, J. Benovic (2007)
Regulation of receptor trafficking by GRKs and arrestins.Annual review of physiology, 69
Tsung-Chieh Lin, M. Hsiao (2017)
Ghrelin and cancer progression.Biochimica et biophysica acta. Reviews on cancer, 1868 1
P. Slobbe, A. Poot, A. Windhorst, G. Dongen (2012)
PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET.Drug discovery today, 17 21-22
M. Niesen, Supriyo Bhattacharya, N. Vaidehi (2011)
The role of conformational ensembles in ligand recognition in G-protein coupled receptors.Journal of the American Chemical Society, 133 33
L. Chopin, C. Walpole, I. Seim, Peter Cunningham, R. Murray, E. Whiteside, P. Josh, A. Herington (2011)
Ghrelin and cancerMolecular and Cellular Endocrinology, 340
Isabelle Tranoy‐Opalinski, Antony Fernandes, Mikaël Thomas, J. Gesson, S. Papot (2008)
Design of self-immolative linkers for tumour-activated prodrug therapy.Anti-cancer agents in medicinal chemistry, 8 6
Mazen Jamous, U. Haberkorn, W. Mier (2013)
Synthesis of Peptide Radiopharmaceuticals for the Therapy and Diagnosis of Tumor DiseasesMolecules, 18
M. Volante, R. Rosas, E. Allia, R. Granata, A. Baragli, G. Muccioli, M. Papotti (2008)
Somatostatin, cortistatin and their receptors in tumoursMolecular and Cellular Endocrinology, 286
M. Kovács, B. Vincze, J. Horváth, J. Seprődi (2007)
Structure–activity study on the LH- and FSH-releasing and anticancer effects of gonadotropin-releasing hormone (GnRH)-III analogsPeptides, 28
Silvia Lehenberger, C. Barkhausen, Susan Cohrs, E. Fischer, J. Grünberg, A. Hohn, U. Köster, R. Schibli, A. Türler, K. Zhernosekov (2010)
The low-energy β(-) and electron emitter (161)Tb as an alternative to (177)Lu for targeted radionuclide therapy.Nuclear medicine and biology, 38 6
(2008)
The global burden of disease: 2004 update
S. Hofmann, S. Maschauer, T. Kuwert, A. Beck‐Sickinger, O. Prante (2015)
Synthesis and in vitro and in vivo evaluation of an (18)F-labeled neuropeptide Y analogue for imaging of breast cancer by PET.Molecular pharmaceutics, 12 4
Min Yi, Hekai Li, Zhiye Wu, Jianyun Yan, Qicai Liu, Caiwen Ou, Minsheng Chen (2017)
A Promising Therapeutic Target for Metabolic Diseases: Neuropeptide Y Receptors in HumansCellular Physiology and Biochemistry, 45
Sadaaki Kimura, S. Masunaga, Tomohiro Harada, Y. Kawamura, S. Ueda, K. Okuda, H. Nagasawa (2011)
Synthesis and evaluation of cyclic RGD-boron cluster conjugates to develop tumor-selective boron carriers for boron neutron capture therapy.Bioorganic & medicinal chemistry, 19 5
Shuang Liu (2008)
Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides.Advanced drug delivery reviews, 60 12
C. Kumar (2003)
Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis.Current drug targets, 4 2
J. Drappatz, A. Brenner, E. Wong, A. Eichler, D. Schiff, M. Groves, T. Mikkelsen, S. Rosenfeld, J. Sarantopoulos, C. Meyers, R. Fielding, K. Elian, Xiaolin Wang, B. Lawrence, M. Shing, S. Kelsey, J. Castaigne, P. Wen (2013)
Phase I Study of GRN1005 in Recurrent Malignant GliomaClinical Cancer Research, 19
M. Kojima, K. Kangawa (2005)
Ghrelin: structure and function.Physiological reviews, 85 2
A. Nagy, A. Schally, P. Armatis, K. Szepesházi, G. Halmos, M. Kovács, M. Zarándi, K. Groot, M. Miyazaki, A. Jungwirth, J. Horváth (1996)
Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent.Proceedings of the National Academy of Sciences of the United States of America, 93 14
W. Graybill, R. Coleman (2014)
Vintafolide: a novel targeted agent for epithelial ovarian cancer.Future oncology, 10 4
I. Vhora, Sushilkumar Patil, P. Bhatt, Ravi Gandhi, Dipesh Baradia, A. Misra (2014)
Receptor-targeted drug delivery: current perspective and challenges.Therapeutic delivery, 5 9
K. Cameron, S. Bhattacharya, A. Loomis (2014)
Small molecule ghrelin receptor inverse agonists and antagonists.Journal of medicinal chemistry, 57 21
H. Hosoda, M. Kojima, K. Kangawa (2006)
Biological, physiological, and pharmacological aspects of ghrelin.Journal of pharmacological sciences, 100 5
R. Deberardinis, N. Chandel (2016)
Fundamentals of cancer metabolismScience Advances, 2
T. Betzel, T. Hess, B. Waser, J. Reubi, F. Roesch (2008)
closo-borane conjugated regulatory peptides retain high biological affinity: synthesis of closo-borane conjugated Tyr(3)-octreotate derivatives for BNCT.Bioconjugate chemistry, 19 9
J. Grünberg, Dennis Lindenblatt, H. Dorrer, Susan Cohrs, K. Zhernosekov, U. Köster, A. Türler, E. Fischer, R. Schibli (2014)
Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer modelEuropean Journal of Nuclear Medicine and Molecular Imaging, 41
C. Spicer, Coline Jumeaux, B. Gupta, M. Stevens (2018)
Peer-reviewed version of the manuscript published in final form at Chemical Society Reviews (2018) Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications
Dennis Worm, Paul Hoppenz, Sylvia Els‐Heindl, Martin Kellert, R. Kuhnert, Stefan Saretz, J. Köbberling, B. Riedl, E. Hey‐Hawkins, A. Beck‐Sickinger (2019)
Selective neuropeptide Y conjugates with maximized carborane loading as promising boron delivery agents for boron neutron capture therapy.Journal of medicinal chemistry
I. Ramos-Álvarez, P. Moreno, S. Mantey, Taichi Nakamura, B. Nuche-Berenguer, T. Moody, D. Coy, R. Jensen (2015)
Insights into bombesin receptors and ligands: Highlighting recent advancesPeptides, 72
Ilka Böhme, Jan Stichel, C. Walther, K. Mörl, A. Beck‐Sickinger (2008)
Agonist induced receptor internalization of neuropeptide Y receptor subtypes depends on third intracellular loop and C-terminus.Cellular signalling, 20 10
M. Hawthorne (1993)
The Role of Chemistry in the Development of Boron Neutron Capture Therapy of CancerAngewandte Chemie, 32
Lindsey Torre, F. Bray, R. Siegel, J. Ferlay, J. Lortet-Tieulent, A. Jemal (2015)
Global cancer statistics, 2012CA: A Cancer Journal for Clinicians, 65
Micah Luderer, P. Puente, A. Azab (2015)
Advancements in Tumor Targeting Strategies for Boron Neutron Capture TherapyPharmaceutical Research, 32
S. Seitz, A. Schally, A. Treszl, A. Papadia, F. Rick, L. Szalontay, K. Szepesházi, O. Ortmann, G. Halmos, F. Hohla, S. Buchholz (2009)
Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibitionAnti-Cancer Drugs, 20
Verena Ahrens, Katja Kostelnik, R. Rennert, David Böhme, S. Kalkhof, David Kosel, L. Weber, M. Bergen, A. Beck‐Sickinger (2015)
A cleavable cytolysin-neuropeptide Y bioconjugate enables specific drug delivery and demonstrates intracellular mode of action.Journal of controlled release : official journal of the Controlled Release Society, 209
Jacek Capala, R. Barth, Moise Bendayan, Michel Lauzon, D. Adams, A. Soloway, R. Fenstermaker, Jörgen Carlsson (1996)
Boronated epidermal growth factor as a potential targeting agent for boron neutron capture therapy of brain tumors.Bioconjugate chemistry, 7 1
Vikas Malhotra, M. Perry (2003)
Classical Chemotherapy: Mechanisms, Toxicities and the Therapeutc WindowCancer Biology & Therapy, 2
Claes Wahlestedt, Donald Reis (1993)
Neuropeptide Y-related peptides and their receptors--are the receptors potential therapeutic drug targets?Annual review of pharmacology and toxicology, 33
D. Wild, M. Fani, Richard Fischer, L. Pozzo, F. Kaul, S. Krebs, Richard Fischer, J. Rivier, J. Reubi, H. Maecke, W. Weber (2014)
Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot StudyThe Journal of Nuclear Medicine, 55
A. Nagy, A. Schally, G. Halmos, P. Armatis, R. Cai, V. Csernus, V. Csernus, M. Kovács, M. Kovács, M. Koppán, M. Koppán, K. Szepesházi, Z. Kahán (1998)
Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.Proceedings of the National Academy of Sciences of the United States of America, 95 4
Minglu Chang, Fang Zhang, Ting Wei, Tiantian Zuo, Yuanyuan Guan, Guimei Lin, W. Shao (2016)
Smart linkers in polymer–drug conjugates for tumor-targeted deliveryJournal of Drug Targeting, 24
Y. Patel (1999)
Somatostatin and Its Receptor FamilyFrontiers in Neuroendocrinology, 20
(2015)
Clarkn, Gynecol. Oncol
Gong Wu, R. Barth, Weilian Yang, Madhumita Chatterjee, W. Tjarks, M. Ciesielski, R. Fenstermaker (2004)
Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy.Bioconjugate chemistry, 15 1
David Böhme, A. Beck‐Sickinger (2015)
Drug delivery and release systems for targeted tumor therapyJournal of Peptide Science, 21
C. Dong, Z. Liu, F. Wang (2013)
Peptide-based radiopharmaceuticals for targeted tumor therapy.Current medicinal chemistry, 21 1
T. Baudino (2015)
Targeted Cancer Therapy: The Next Generation of Cancer Treatment.Current drug discovery technologies, 12 1
P. Limonta, M. Marelli, S. Mai, M. Motta, L. Martini, R. Moretti (2012)
GnRH receptors in cancer: from cell biology to novel targeted therapeutic strategies.Endocrine reviews, 33 5
R. Söll, R. Söll, Michaela Dinger, I. Lundell, Dan Larhammer, A. Beck‐Sickinger (2001)
Novel analogues of neuropeptide Y with a preference for the Y1-receptor.European journal of biochemistry, 268 10
M. Freissmuth, P. Casey, A. Gilman (1989)
G proteins control diverse pathways of transmembrane signaling 1The FASEB Journal, 3
Charity Wayua, Jyoti Roy, K. Putt, Philip Low (2015)
Selective Tumor Targeting of Desacetyl Vinblastine Hydrazide and Tubulysin B via Conjugation to a Cholecystokinin 2 Receptor (CCK2R) LigandMolecular Pharmaceutics, 12
J. Strosberg, G. El-Haddad, E. Wolin, A. Hendifar, James Yao, B. Chasen, E. Mittra, P. Kunz, M. Kulke, H. Jacene, D. Bushnell, T. O'Dorisio, R. Baum, H. Kulkarni, M. Caplin, R. Lebtahi, T. Hobday, E. Delpassand, E. Cutsem, A. Benson, R. Srirajaskanthan, M. Pavel, J. Mora, J. Berlin, E. Grande, N. Reed, E. Seregni, K. Öberg, M. Sierra, P. Santoro, T. Thevenet, J. Erion, P. Ruszniewski, D. Kwekkeboom, E. Krenning (2017)
Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine TumorsThe New England Journal of Medicine, 376
Zhangsen Yu, Yuanzhi Xia, Jie Xing, Zihou Li, Jianjun Zhen, Yinhua Jin, Yuchen Tian, Chuang Liu, Zhenqi Jiang, Juan Li, A. Wu (2018)
Y1-receptor-ligand-functionalized ultrasmall upconversion nanoparticles for tumor-targeted trimodality imaging and photodynamic therapy with low toxicity.Nanoscale, 10 36
A. Wittig, Wolfgang Sauerwein, J. Coderre (2000)
Mechanisms of Transport of p-Borono-Phenylalanine through the Cell Membrane In Vitro, 153
D. Cornelio, R. Roesler, G. Schwartsmann (2007)
Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy.Annals of oncology : official journal of the European Society for Medical Oncology, 18 9
A. Nguyen, Natalie Mitchell, Shu Lin, L. Macia, E. Yulyaningsih, P. Baldock, R. Enriquez, Lei Zhang, Yanchuan Shi, S. Zolotukhin, H. Herzog, A. Sainsbury (2012)
Y1 and Y5 Receptors Are Both Required for the Regulation of Food Intake and Energy Homeostasis in MicePLoS ONE, 7
N. Hirmas, Raya Jadaan, Akram Al-Ibraheem (2018)
Peptide Receptor Radionuclide Therapy and the Treatment of Gastroentero-pancreatic Neuroendocrine Tumors: Current Findings and Future PerspectivesNuclear Medicine and Molecular Imaging, 52
Christopher Johnson, T. Shelton, Charles Smith, Lixin Ma, M. Perry, W. Volkert, T. Hoffman (2006)
Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice.Cancer biotherapy & radiopharmaceuticals, 21 2
J. Cwikła, A. Sankowski, N. Seklecka, J. Buscombe, A. Nasierowska-Guttmejer, K. Jeziorski, R. Mikołajczak, D. Pawlak, K. Stępień, J. Walecki (2010)
Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study.Annals of oncology : official journal of the European Society for Medical Oncology, 21 4
B. Ueberberg, N. Unger, W. Saeger, K. Mann, S. Petersenn (2009)
Expression of Ghrelin and its Receptor in Human TissuesHormone and Metabolic Research, 41
Alyson Weidmann, Alexis Komor, J. Barton (2014)
Targeted Chemotherapy with Metal ComplexesComments on Inorganic Chemistry, 34
S. Naqvi, T. Matzow, C. Finucane, S. Nagra, M. Ishfaq, S. Mather, J. Sosabowski (2010)
Insertion of a lysosomal enzyme cleavage site into the sequence of a radiolabeled neuropeptide influences cell trafficking in vitro and in vivo.Cancer biotherapy & radiopharmaceuticals, 25 1
P. Holzer, Florian Reichmann, A. Farzi (2012)
Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut–brain axisNeuropeptides, 46
A. Howard, S. Feighner, D. Cully, J. Arena, P. Liberator, C. Rosenblum, M. Hamelin, D. Hreniuk, O. Palyha, Jennifer Anderson, P. Paress, Carmen Diaz, Michael Chou, Ken Liu, K. McKee, S. Pong, L. Chaung, A. Elbrecht, M. Dashkevicz, R. Heavens, M. Rigby, D. Sirinathsinghji, D. Dean, D. Melillo, A. Patchett, R. Nargund, P. Griffin, J. DeMartino, S. Gupta, J. Schaeffer, Roy Smith, L. Ploeg (1996)
A Receptor in Pituitary and Hypothalamus That Functions in Growth Hormone ReleaseScience, 273
S. Ohkuma, B. Poole (1978)
Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents.Proceedings of the National Academy of Sciences of the United States of America, 75 7
M. Bhat, Nathaniel Robichaud, Laura Hulea, N. Sonenberg, J. Pelletier, I. Topisirovic (2015)
Targeting the translation machinery in cancerNature Reviews Drug Discovery, 14
Gisela Olias, C. Viollet, H. Kusserow, J. Epelbaum, W. Meyerhof (2004)
Regulation and function of somatostatin receptorsJournal of Neurochemistry, 89
Weilian Yang, Gong Wu, R. Barth, Michele Swindall, A. Bandyopadhyaya, W. Tjarks, K. Tordoff, M. Moeschberger, T. Sferra, P. Binns, K. Riley, M. Ciesielski, R. Fenstermaker, C. Wikstrand (2008)
Molecular Targeting and Treatment of Composite EGFR and EGFRvIII-Positive Gliomas Using Boronated Monoclonal AntibodiesClinical Cancer Research, 14
B. Kam, J. Teunissen, E. Krenning, W. Herder, Saima Khan, E. Vliet, D. Kwekkeboom (2012)
Lutetium-labelled peptides for therapy of neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 39
G. Emons, G. Gorchev, P. Harter, P. Wimberger, A. Stähle, L. Hanker, F. Hilpert, M. Beckmann, P. Dall, C. Gründker, H. Sindermann, J. Sehouli (2014)
Efficacy and Safety of AEZS-108 (LHRH Agonist Linked to Doxorubicin) in Women With Advanced or Recurrent Endometrial Cancer Expressing LHRH ReceptorsInternational Journal of Gynecological Cancer, 24
S. Pfister, A. Ashworth (2017)
Marked for death: targeting epigenetic changes in cancerNature Reviews Drug Discovery, 16
M. Pierschbacher, E. Ruoslahti (1984)
Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the moleculeNature, 309
Zhaofei Liu, Fan Wang, Xiaoyuan Chen (2011)
Integrin Targeted Delivery of RadiotherapeuticsTheranostics, 1
S. Good, M. Walter, B. Waser, Xue-juan Wang, J. Müller-Brand, M. Béhé, J. Reubi, H. Maecke (2008)
Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 35
E. Schirrmacher, R. Schirrmacher, C. Beck, W. Mier, N. Trautman, F. Rösch (2003)
Synthesis of a Tyr3-octreotate conjugated closo-carborane [HC2B10H10]: a potential compound for boron neutron capture therapyTetrahedron Letters, 44
K. Kokko, M. Hadden, K. Orwig, J. Mazella, Thomas Dix (2003)
In vitro analysis of stable, receptor-selective neurotensin[8-13] analogues.Journal of medicinal chemistry, 46 19
Sylvia Els, E. Schild, P. Petersen, T. Kilian, J. Mokrosiński, T. Frimurer, C. Chollet, T. Schwartz, B. Holst, A. Beck‐Sickinger (2012)
An aromatic region to induce a switch between agonism and inverse agonism at the ghrelin receptor.Journal of medicinal chemistry, 55 17
P. Carpino (2002)
Recent developments in ghrelin receptor (GHS-R1a) agonists and antagonistsExpert Opinion on Therapeutic Patents, 12
Verena Ahrens, René Frank, Solveig Boehnke, C. Schütz, G. Hampel, Dorothée Iffland, N. Bings, E. Hey‐Hawkins, A. Beck‐Sickinger (2015)
Receptor‐Mediated Uptake of Boron‐Rich Neuropeptide Y Analogues for Boron Neutron Capture TherapyChemMedChem, 10
T. Müller, R. Nogueiras, M. Andermann, Z. Andrews, S. Anker, J. Argente, R. Batterham, S. Benoit, C. Bowers, F. Broglio, F. Casanueva, D. D’Alessio, I. Depoortere, A. Geliebter, E. Ghigo, P. Cole, M. Cowley, D. Cummings, A. Dagher, S. Diano, S. Dickson, C. Diéguez, R. Granata, H. Grill, K. Grove, K. Habegger, K. Heppner, M. Heiman, L. Holsen, B. Holst, A. Inui, J. Jansson, H. Kirchner, M. Korbonits, B. Laferrère, C. Leroux, M. López, S. Morin, M. Nakazato, R. Nass, D. Perez-Tilve, P. Pfluger, T. Schwartz, R. Seeley, M. Sleeman, Y. Sun, L. Sussel, J. Tong, M. Thorner, A. Lely, L. Ploeg, J. Zigman, M. Kojima, K. Kangawa, R. Smith, T. Horvath, M. Tschöp (2015)
GhrelinMolecular Metabolism, 4
J. Pantel, M. Legendre, S. Cabrol, L. Hilal, Y. Hajaji, S. Morisset, S. Nivot, Marie-Pierre Vié-Luton, D. Grouselle, M. Kerdanet, A. Kadiri, J. Epelbaum, Y. Bouc, S. Amselem (2006)
Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature.The Journal of clinical investigation, 116 3
A. Schally, A. Nagy (1999)
Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors.European journal of endocrinology, 141 1
(2015)
Global Cancer Facts & Figures
W. Mier, D. Gabel, U. Haberkorn, M. Eisenhut (2004)
Conjugation of the closo‐Borane Mercaptoundecahydrododecaborate (BSH) to a Tumour Selective PeptideZeitschrift für anorganische und allgemeine Chemie, 630
J. Desgrosellier, D. Cheresh (2010)
Integrins in cancer: biological implications and therapeutic opportunitiesNature Reviews Cancer, 10
E. Hindié, P. Zanotti-Fregonara, M. Quinto, C. Morgat, C. Champion (2016)
Dose Deposits from 90Y, 177Lu, 111In, and 161Tb in Micrometastases of Various Sizes: Implications for Radiopharmaceutical TherapyThe Journal of Nuclear Medicine, 57
M. Wieduwilt, M. Moasser (2008)
The epidermal growth factor receptor family: Biology driving targeted therapeuticsCellular and Molecular Life Sciences, 65
J. O’Donoghue, M. Bardiès, T. Wheldon (1995)
Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 36 10
P. Seshacharyulu, M. Ponnusamy, D. Haridas, Maneesh Jain, A. Ganti, S. Batra (2012)
Targeting the EGFR signaling pathway in cancer therapyExpert Opinion on Therapeutic Targets, 16
René Frank, Verena Ahrens, Solveig Boehnke, A. Beck‐Sickinger, E. Hey‐Hawkins (2016)
Charge‐Compensated Metallacarborane Building Blocks for Conjugation with PeptidesChemBioChem, 17
J. Valliant, Katharina Guenther, A. King, P. Morel, P. Schaffer, Oyebola Sogbein, K. Stephenson (2002)
The medicinal chemistry of carboranesCoordination Chemistry Reviews, 232
Qinlian Jiao, Lei Bi, Yidan Ren, Shuliang Song, Qin Wang, Yunshan Wang (2018)
Advances in studies of tyrosine kinase inhibitors and their acquired resistanceMolecular Cancer, 17
J. Vasir, V. Labhasetwar (2005)
Targeted Drug Delivery in Cancer TherapyTechnology in Cancer Research & Treatment, 4
Yue Yin, Yin Li, Weizhen Zhang (2014)
The Growth Hormone Secretagogue Receptor: Its Intracellular Signaling and RegulationInternational Journal of Molecular Sciences, 15
Chengcheng Zhang, Jinhe Pan, Kuo‐Shyan Lin, Iulia Dude, Joseph Lau, J. Zeisler, Helen Merkens, S. Jenni, B. Guérin, F. Bénard (2016)
Targeting the Neuropeptide Y1 Receptor for Cancer Imaging by Positron Emission Tomography Using Novel Truncated Peptides.Molecular pharmaceutics, 13 11
M. Körner, B. Waser, J. Reubi (2008)
High Expression of Neuropeptide Y1 Receptors in Ewing Sarcoma TumorsClinical Cancer Research, 14
Shibin Ai, Tao Jia, Weilun Ai, Jianli Duan, Yongmei Liu, J. Chen, Xin Liu, Fan Yang, Yuanpeng Tian, Zebo Huang (2013)
Targeted delivery of doxorubicin through conjugation with EGF receptor–binding peptide overcomes drug resistance in human colon cancer cellsBritish Journal of Pharmacology, 168
S. Marso, S. Bain, A. Consoli, F. Eliaschewitz, E. Jódar, Lawrence Leiter, I. Lingvay, J. Rosenstock, J. Seufert, M. Warren, V. Woo, O. Hansen, A. Holst, Jonas Pettersson, T. Vilsbøll (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.The New England journal of medicine, 375 19
Bo Tang, Xin Yong, Rui Xie, Qian-wei Li, Shiming Yang (2014)
Vasoactive intestinal peptide receptor-based imaging and treatment of tumors (Review).International journal of oncology, 44 4
A. Wren, L. Seal, Mark Cohen, A. Brynes, G. Frost, K. Murphy, W. Dhillo, M. Ghatei, S. Bloom (2001)
Ghrelin enhances appetite and increases food intake in humans.The Journal of clinical endocrinology and metabolism, 86 12
Matthias Scholz, E. Hey‐Hawkins (2011)
Carbaboranes as pharmacophores: properties, synthesis, and application strategies.Chemical reviews, 111 11
S. Froidevaux, M. Calame-Christe, H. Tanner, A. Eberle (2005)
Melanoma targeting with DOTA-alpha-melanocyte-stimulating hormone analogs: structural parameters affecting tumor uptake and kidney uptake.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 46 5
Jin-Qiang Hou, M. Kovacs, S. Dhanvantari, L. Luyt (2018)
Development of Candidates for Positron Emission Tomography (PET) Imaging of Ghrelin Receptor in Disease: Design, Synthesis, and Evaluation of Fluorine-Bearing Quinazolinone Derivatives.Journal of medicinal chemistry, 61 3
L. Lantry, E. Cappelletti, Mary Maddalena, Jaclyn Fox, Weiwei Feng, Jianqing Chen, Regi Thomas, S. Eaton, N. Bogdan, T. Arunachalam, J. Reubi, N. Raju, E. Metcalfe, L. Lattuada, K. Linder, R. Swenson, M. Tweedle, A. Nunn (2006)
177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 47 7
G. Díaz-Soto, E. Romero, J. Pérez-Castrillón, O. Jáuregui, D. Román (2016)
Parathyroid Hormone Polymorphism RS6254 is Associated with the Development and Severity of Osteoporosis in Asymptomatic but not Normocalcemic HyperthyroidismHormone and Metabolic Research, 48
R. Barth, J. Coderre, M. Vicente, T. Blue (2005)
Boron Neutron Capture Therapy of Cancer: Current Status and Future ProspectsClinical Cancer Research, 11
V. Erspamer, G. Erspamer, M. Inselvini (1970)
Some pharmacological actions of alytesin and bombesinJournal of Pharmacy and Pharmacology, 22
Hong Xiao (2006)
Inaugural Article: Insights into the mechanism of microtubule stabilization by TaxolProceedings of the National Academy of Sciences of the United States of America
R. Barth, P. Mi, Weilian Yang (2018)
Boron delivery agents for neutron capture therapy of cancerCancer Communications, 38
M. Ginj, Hanwen Zhang, B. Waser, R. Cescato, D. Wild, Xue-juan Wang, J. Érchegyi, J. Rivier, H. Mäcke, J. Reubi (2006)
Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumorsProceedings of the National Academy of Sciences, 103
Y. Gilad, E. Noy, H. Senderowitz, A. Albeck, M. Firer, G. Gellerman (2016)
Dual‐drug RGD conjugates provide enhanced cytotoxicity to melanoma and non‐small lung cancer cellsPeptide Science, 106
Veronika Mäde, Stefanie Babilon, N. Jolly, Lizzy Wanka, K. Bellmann-Sickert, Luis Gimenez, K. Mörl, H. Cox, V. Gurevich, A. Beck‐Sickinger (2014)
Peptide modifications differentially alter G protein-coupled receptor internalization and signaling bias.Angewandte Chemie, 53 38
M. Körner, J. Reubi (2007)
NPY receptors in human cancer: A review of current knowledgePeptides, 28
R. Valkema, M. Jong, W. Bakker, W. Breeman, P. Kooij, P. Lugtenburg, F. Jong, A. Christiansen, B. Kam, W. Herder, M. Stridsberg, J. Lindemans, G. Ensing, E. Krenning (2002)
Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience.Seminars in nuclear medicine, 32 2
Zhen-lin Yang, Shuo Han, M. Keller, A. Kaiser, B. Bender, Mathias Bosse, Kerstin Burkert, L. Kögler, David Wifling, G. Bernhardt, N. Plank, Timo Littmann, P. Schmidt, C. Yi, Beibei Li, S. Ye, Rong-guang Zhang, Bo Xu, D. Larhammar, R. Stevens, D. Huster, J. Meiler, Qiang Zhao, A. Beck‐Sickinger, A. Buschauer, Beili Wu (2018)
Structural basis of ligand binding modes at the neuropeptide Y Y1 receptorNature, 556
V. Goffredo, A. Paradiso, G. Ranieri, C. Gadaleta (2011)
Yttrium-90 (90Y) in the principal radionuclide therapies: an efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999-2009).Critical reviews in oncology/hematology, 80 3
F. Kratz, Ivonne Müller, Claudia Ryppa, A. Warnecke (2008)
Prodrug Strategies in Anticancer ChemotherapyChemMedChem, 3
M. Janssen, W. Oyen, I. Dijkgraaf, L. Massuger, C. Frielink, D. Edwards, M. Rajopadhye, H. Boonstra, F. Corstens, O. Boerman (2002)
Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.Cancer research, 62 21
R. Valkema, S. Pauwels, L. Kvols, R. Barone, F. Jamar, W. Bakker, D. Kwekkeboom, H. Bouterfa, E. Krenning (2006)
Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors.Seminars in nuclear medicine, 36 2
Zonghai Li, Ruijiao Zhao, Xianghua Wu, Ye Sun, M. Yao, Jinjun Li, Yuhong Xu, Jian-ren Gu (2005)
Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeuticsThe FASEB Journal, 19
L. Zhang, G. Bulaj (2012)
Converting peptides into drug leads by lipidation.Current medicinal chemistry, 19 11
Luca Gaviglio, A. Gross, N. Metzler‐Nolte, M. Ravera (2012)
Synthesis and in vitro cytotoxicity of cis,cis,trans-diamminedichloridodisuccinatoplatinum(IV)-peptide bioconjugates.Metallomics : integrated biometal science, 4 3
A. Schally, J. Engel, G. Emons, N. Block, J. Pinski (2011)
Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors.Current drug delivery, 8 1
T. Karagiannis (2007)
Comparison of different classes of radionuclides for potential use in radioimmunotherapy.Hellenic journal of nuclear medicine, 10 2
E. Ragozin, A. Hesin, A. Bazylevich, H. Tuchinsky, A. Bovina, T. Zahavi, M. Oron-Herman, G. Kostenich, M. Firer, T. Rubinek, I. Wolf, G. Luboshits, M. Sherman, G. Gellerman (2018)
New somatostatin-drug conjugates for effective targeting pancreatic cancer.Bioorganic & medicinal chemistry, 26 13
S. Brothers, C. Wahlestedt (2010)
Therapeutic potential of neuropeptide Y (NPY) receptor ligandsEMBO Molecular Medicine, 2
Zhaofei Liu, Jiyun Shi, Bing Jia, Zilin Yu, Yan Liu, Hui-yun Zhao, Fang Li, Jie Tian, Xiaoyuan Chen, Shuang Liu, Fan Wang (2011)
Two ⁹⁰Y-labeled multimeric RGD peptides RGD4 and 3PRGD2 for integrin targeted radionuclide therapy.Molecular pharmaceutics, 8 2
B. Holst, A. Cygankiewicz, T. Jensen, M. Ankersen, T. Schwartz (2003)
High constitutive signaling of the ghrelin receptor--identification of a potent inverse agonist.Molecular endocrinology, 17 11
R. Millar (2005)
GnRHs and GnRH receptors.Animal reproduction science, 88 1-2
B. Holst, T. Schwartz (2004)
Constitutive ghrelin receptor activity as a signaling set-point in appetite regulation.Trends in pharmacological sciences, 25 3
A. Oza, I. Vergote, L. Gilbert, Lucy, P. Ghatage, A. Lisyankaya, S. Ghamande, S. Chambers, J. Arranz, D. Provencher, P. Bessette, A. Amnon, J. Symanowski, R. Penson, R. Naumann, R. Clark (2015)
A randomized double-blind phase III trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD/Doxil®/Caelyx®) in combination versus PLD in participants with platinum-resistant ovarian cancer (PROCEED) (NCT01170650)Gynecologic Oncology, 137
Claudia Ryppa, Hagit Mann-Steinberg, I. Fichtner, H. Weber, R. Satchi‐Fainaro, M. Biniossek, F. Kratz (2008)
In vitro and in vivo evaluation of doxorubicin conjugates with the divalent peptide E-[c(RGDfK)2] that targets integrin alphavbeta3.Bioconjugate chemistry, 19 7
Lichun Sun, D. Coy (2011)
Somatostatin receptor-targeted anti-cancer therapy.Current drug delivery, 8 1
M. Schwartz, M. Schaller, M. Ginsberg (1995)
Integrins: emerging paradigms of signal transduction.Annual review of cell and developmental biology, 11
B. Holst, M. Lang, E. Brandt, A. Bach, A. Howard, T. Frimurer, A. Beck‐Sickinger, T. Schwartz (2006)
Ghrelin Receptor Inverse Agonists: Identification of an Active Peptide Core and Its Interaction Epitopes on the ReceptorMolecular Pharmacology, 70
D. Zwanziger, I. Khan, I. Neundorf, S. Sieger, L. Lehmann, M. Friebe, L. Dinkelborg, A. Beck‐Sickinger (2008)
Novel chemically modified analogues of neuropeptide Y for tumor targeting.Bioconjugate chemistry, 19 7
A. Soloway, W. Tjarks, B. Barnum, F. Rong, R. Barth, Iwona Codogni, J. Wilson (1998)
The Chemistry of Neutron Capture Therapy.Chemical reviews, 98 4
Genevieve Housman, Shannon Byler, S. Heerboth, K. Lapinska, Mckenna Longacre, N. Snyder, S. Sarkar (2014)
Drug Resistance in Cancer: An OverviewCancers, 6
Jill Smith, L. Fonkoua, T. Moody (2016)
The Role of Gastrin and CCK Receptors in Pancreatic Cancer and other MalignanciesInternational Journal of Biological Sciences, 12
C. Gründker, G. Emons (2017)
The Role of Gonadotropin-Releasing Hormone in Cancer Cell Proliferation and MetastasisFrontiers in Endocrinology, 8
V. Delplace, P. Couvreur, J. Nicolas (2014)
Recent trends in the design of anticancer polymer prodrug nanocarriersPolymer Chemistry, 5
Hong-chang Shen, D. Hu, Jiajun Du, Xiuwen Wang, Yanguo Liu, Ya-wei Wang, Jun-min Wei, D. Ma, Pu Wang, Lei Li (2008)
Paclitaxel-octreotide conjugates in tumor growth inhibition of A549 human non-small cell lung cancer xenografted into nude mice.European journal of pharmacology, 601 1-3
H. Helmbach, Evelyn Rossmann, M. Kern, D. Schadendorf (2001)
Drug‐resistance in human melanomaInternational Journal of Cancer, 93
M. Janssen, C. Frielink, I. Dijkgraaf, W. Oyen, D. Edwards, Shuang Liu, M. Rajopadhye, L. Massuger, F. Corstens, O. Boerman (2004)
Improved tumor targeting of radiolabeled RGD peptides using rapid dose fractionation.Cancer biotherapy & radiopharmaceuticals, 19 4
Verena Ahrens, K. Bellmann-Sickert, A. Beck‐Sickinger (2012)
Peptides and peptide conjugates: therapeutics on the upward path.Future medicinal chemistry, 4 12
J. Engel, A. Schally, G. Halmos, Benjamin Baker, A. Nagy, Gunhild Keller (2005)
Targeted therapy with a cytotoxic somatostatin analog, AN‐238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR‐1Cancer, 104
R. Ochakovskaya, L. Osorio, D. Goldenberg, M. Mattes (2001)
Therapy of disseminated B-cell lymphoma xenografts in severe combined immunodeficient mice with an anti-CD74 antibody conjugated with (111)indium, (67)gallium, or (90)yttrium.Clinical cancer research : an official journal of the American Association for Cancer Research, 7 6
C. Müller, Josefine Reber, S. Haller, H. Dorrer, P. Bernhardt, K. Zhernosekov, A. Türler, R. Schibli (2014)
Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugateEuropean Journal of Nuclear Medicine and Molecular Imaging, 41
S. Rizvi, S. Naqvi, S. Roohi, T. Sherazi, Rashid Rasheed (2018)
177Lu-DOTA-coupled minigastrin peptides: promising theranostic agents in neuroendocrine cancersMolecular Biology Reports, 45
Monroe Wall (1998)
Camptothecin and taxol: Discovery to clinicMedicinal Research Reviews, 18
S. Froidevaux, A. Eberle (2002)
HOMOLOGOUS REGULATION OF MELANOCORTIN-1 RECEPTOR (MC1R) EXPRESSION IN MELANOMA TUMOR CELLS IN VIVOJournal of Receptors and Signal Transduction, 22
S. Dickson, E. Egecioglu, S. Landgren, K. Skibicka, J. Engel, E. Jerlhag (2011)
The role of the central ghrelin system in reward from food and chemical drugsMolecular and Cellular Endocrinology, 340
J. Reubi (2007)
Targeting CCK receptors in human cancers.Current topics in medicinal chemistry, 7 12
B. Holst, J. Mokrosiński, M. Lang, E. Brandt, R. Nygaard, T. Frimurer, A. Beck‐Sickinger, T. Schwartz (2007)
Identification of an Efficacy Switch Region in the Ghrelin Receptor Responsible for Interchange between Agonism and Inverse Agonism*Journal of Biological Chemistry, 282
Verena Ahrens, René Frank, S. Stadlbauer, A. Beck‐Sickinger, E. Hey‐Hawkins (2011)
Incorporation of ortho-carbaboranyl-Nε-modified L-lysine into neuropeptide Y receptor Y1- and Y2-selective analogues.Journal of medicinal chemistry, 54 7
Juan Li, Yang Du, Zhenqi Jiang, Yuchen Tian, Nianxiang Qiu, Yinjie Wang, M. Lqbal, Menying Hu, Ruifen Zou, Lijia Luo, Shiyu Du, Jie Tian, A. Wu (2018)
Y1 receptor ligand-based nanomicelle as a novel nanoprobe for glioma-targeted imaging and therapy.Nanoscale, 10 13
T. Pradhan, Tatsuro Katsuno, John Taylor, Sun Kim, R. Ryan, S. Mantey, Patrick Donohue, H. Weber, Eduardo Sainz, J. Battey, David Coy, Robert Jensen (1998)
Identification of a unique ligand which has high affinity for all four bombesin receptor subtypes.European journal of pharmacology, 343 2-3
M. Langer, F. Kratz, B. Rothen‐Rutishauser, H. Wunderli‐Allenspach, A. Beck‐Sickinger (2001)
Novel peptide conjugates for tumor-specific chemotherapy.Journal of medicinal chemistry, 44 9
C. Cabrele, A. Beck‐Sickinger (2000)
Molecular characterization of the ligand–receptor interaction of the neuropeptide Y familyJournal of Peptide Science, 6
I. Guryanov, Alex Bondesan, D. Visentini, Andrea Orlandin, B. Biondi, C. Toniolo, F. Formaggio, Antonio Ricci, J. Zanon, W. Cabri (2016)
Innovative chemical synthesis and conformational hints on the lipopeptide liraglutideJournal of Peptide Science, 22
J. Camiña, M. Carreira, S. Messari, C. Llorens-Cortes, Roy Smith, F. Casanueva (2004)
Desensitization and endocytosis mechanisms of ghrelin-activated growth hormone secretagogue receptor 1a.Endocrinology, 145 2
Ainhoa Gutierrez, P. McDonald (2018)
GPCRs: Emerging anti-cancer drug targets.Cellular signalling, 41
E. Dadachova (2010)
Cancer therapy with alpha-emitters labeled peptides.Seminars in nuclear medicine, 40 3
Sylvia Els, A. Beck‐Sickinger, C. Chollet (2010)
Ghrelin receptor: high constitutive activity and methods for developing inverse agonists.Methods in enzymology, 485
Juan Li, Zheyu Shen, Xuehua Ma, Wenzhi Ren, Lingchao Xiang, An Gong, T. Xia, Junming Guo, A. Wu (2015)
Neuropeptide Y Y1 receptors mediate [corrected] targeted delivery of anticancer drug with encapsulated nanoparticles to breast cancer cells with high selectivity and its potential for breast cancer therapy.ACS applied materials & interfaces, 7 9
Charity Wayua, P. Low (2014)
Evaluation of a cholecystokinin 2 receptor-targeted near-infrared dye for fluorescence-guided surgery of cancer.Molecular pharmaceutics, 11 2
M. Kojima, H. Hosoda, Y. Date, M. Nakazato, H. Matsuo, K. Kangawa (1999)
Ghrelin is a growth-hormone-releasing acylated peptide from stomachNature, 402
Luis Leon-Rodriguez, Z. Kovács (2008)
The synthesis and chelation chemistry of DOTA-peptide conjugates.Bioconjugate chemistry, 19 2
P. Carter, P. Senter (2008)
Antibody-Drug Conjugates for Cancer TherapyThe Cancer Journal, 14
S. Frokjaer, D. Otzen (2005)
Protein drug stability: a formulation challengeNature Reviews Drug Discovery, 4
Steven Yu, Kanthi Athreya, Stephen Liu, A. Schally, D. Tsao-Wei, S. Groshen, D. Quinn, T. Dorff, S. Xiong, J. Engel, J. Pinski (2017)
A Phase II Trial of AEZS‐108 in Castration‐ and Taxane‐Resistant Prostate CancerClinical Genitourinary Cancer, 15
Sibaprasad Bhattacharyya, M. Dixit (2011)
Metallic radionuclides in the development of diagnostic and therapeutic radiopharmaceuticals.Dalton transactions, 40 23
N. Mizuno, H. Itoh (2009)
Functions and Regulatory Mechanisms of Gq-Signaling PathwaysNeurosignals, 17
Dennis Worm, Sylvia Els‐Heindl, Martin Kellert, R. Kuhnert, Stefan Saretz, J. Koebberling, B. Riedl, E. Hey‐Hawkins, A. Beck‐Sickinger (2018)
A stable meta‐carborane enables the generation of boron‐rich peptide agonists targeting the ghrelin receptorJournal of Peptide Science, 24
Madduri Srinivasarao, C. Galliford, P. Low (2015)
Principles in the design of ligand-targeted cancer therapeutics and imaging agentsNature Reviews Drug Discovery, 14
A. Régina, M. Demeule, C. Ché, I. Lavallée, Julie Poirier, R. Gabathuler, R. Béliveau, Castaigne Jp (2008)
Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep‐2British Journal of Pharmacology, 155
I. Vlahov, H. Santhapuram, Paul Kleindl, S. Howard, K. Stanford, C. Leamon (2006)
Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide.Bioorganic & medicinal chemistry letters, 16 19
I. Khan, D. Zwanziger, Ilka Böhme, M. Javed, H. Naseer, S. Hyder, A. Beck‐Sickinger (2010)
Breast-cancer diagnosis by neuropeptide Y analogues: from synthesis to clinical application.Angewandte Chemie, 49 6
L. Sancey, Elisabeth Garanger, Stéphanie Foillard, G. Schoehn, A. Hurbin, C. Albigès-Rizo, D. Boturyn, C. Souchier, A. Grichine, P. Dumy, J. Coll (2009)
Clustering and internalization of integrin alphavbeta3 with a tetrameric RGD-synthetic peptide.Molecular therapy : the journal of the American Society of Gene Therapy, 17 5
Bjørn Sivertsen, M. Lang, T. Frimurer, N. Holliday, A. Bach, Sylvia Els, M. Engelstoft, P. Petersen, A. Madsen, T. Schwartz, A. Beck‐Sickinger, B. Holst (2011)
Unique Interaction Pattern for a Functionally Biased Ghrelin Receptor Agonist*The Journal of Biological Chemistry, 286
R. Michel, Philip Andrews, Adriane Rosario, D. Goldenberg, M. Mattes (2005)
177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo.Nuclear medicine and biology, 32 3
David Böhme, Jan Krieghoff, A. Beck‐Sickinger (2016)
Double Methotrexate-Modified Neuropeptide Y Analogues Express Increased Toxicity and Overcome Drug Resistance in Breast Cancer Cells.Journal of medicinal chemistry, 59 7
R. Barth, MGraca Vicente, O. Harling, W. Kiger, K. Riley, P. Binns, F. Wagner, Minoru Suzuki, T. Aihara, I. Kato, S. Kawabata (2012)
Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancerRadiation Oncology (London, England), 7
Y. Gilad, E. Noy, H. Senderowitz, A. Albeck, M. Firer, G. Gellerman (2016)
Synthesis, biological studies and molecular dynamics of new anticancer RGD-based peptide conjugates for targeted drug delivery.Bioorganic & medicinal chemistry, 24 2
David Böhme, A. Beck‐Sickinger (2015)
Controlling Toxicity of Peptide–Drug Conjugates by Different Chemical Linker StructuresChemMedChem, 10
D. Nikolopoulos, S. Theocharis, G. Kouraklis (2010)
Ghrelin: A potential therapeutic target for cancerRegulatory Peptides, 163
C. Gondi, J. Rao (2013)
Cathepsin B as a cancer targetExpert Opinion on Therapeutic Targets, 17
D. Kwekkeboom, B. Kam, M. Essen, J. Teunissen, C. Eijck, R. Valkema, M. Jong, W. Herder, E. Krenning (2010)
Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.Endocrine-related cancer, 17 1
L. Genestier, R. Paillot, L. Quéméneur, K. Izeradjene, J. Revillard (2000)
Mechanisms of action of methotrexate.Immunopharmacology, 47 2-3
D. Verma, R. Tasan, Herbert Herzog, G. Sperk (2012)
NPY controls fear conditioning and fear extinction by combined action on Y1 and Y2 receptorsBritish Journal of Pharmacology, 166
R. Moldovan, Sylvia Els‐Heindl, Dennis Worm, T. Kniess, M. Kluge, A. Beck‐Sickinger, W. Deuther-Conrad, U. Krügel, P. Brust (2017)
Development of Fluorinated Non-Peptidic Ghrelin Receptor Ligands for Potential Use in Molecular ImagingInternational Journal of Molecular Sciences, 18
M. Jong, W. Bakker, W. Breeman, B. Bernard, L. Hofland, T. Visser, A. Srinivasan, M. Schmidt, M. Béhé, H. Mäcke, E. Krenning (1998)
Pre‐clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor‐targeted scintigraphy and radionuclide therapyInternational Journal of Cancer, 75
(2020)
https://doi.org/10.1158/ 1078-0432.CCR-19-3258
Xiao-jian Zhou, R. Rahmani (2012)
Preclinical and Clinical Pharmacology of Vinca AlkaloidsDrugs, 44
Weilian Yang, R. Barth, Gong Wu, T. Huo, W. Tjarks, M. Ciesielski, R. Fenstermaker, B. Ross, C. Wikstrand, K. Riley, P. Binns (2009)
Convection enhanced delivery of boronated EGF as a molecular targeting agent for neutron capture therapy of brain tumorsJournal of Neuro-Oncology, 95
Fancy Thomas, Kunal Taskar, Vinay Rudraraju, Satyanarayana Goda, H. Thorsheim, Julie Gaasch, R. Mittapalli, D. Palmieri, P. Steeg, P. Lockman, Q. Smith (2009)
Uptake of ANG1005, A Novel Paclitaxel Derivative, Through the Blood-Brain Barrier into Brain and Experimental Brain Metastases of Breast CancerPharmaceutical Research, 26
P. Vlieghe, V. Lisowski, Jean Martinez, M. Khrestchatisky (2010)
Synthetic therapeutic peptides: science and market.Drug discovery today, 15 1-2
K. Strebhardt, A. Ullrich (2008)
Paul Ehrlich's magic bullet concept: 100 years of progressNature Reviews Cancer, 8
G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, L. Gianni (2004)
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and CardiotoxicityPharmacological Reviews, 56
J. Reubi, Mathias Gugger, B. Waser, J. Schaer (2001)
Y(1)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets.Cancer research, 61 11
D. Larhammar (1996)
Evolution of neuropeptide Y, peptide YY and pancreatic polypeptideRegulatory Peptides, 62
Boris Redko, H. Tuchinsky, Tamar Segal, D. Tobi, G. Luboshits, O. Ashur-Fabian, A. Pinhasov, G. Gerlitz, G. Gellerman (2016)
Toward the development of a novel non-RGD cyclic peptide drug conjugate for treatment of human metastatic melanomaOncotarget, 8
H. Herzog, Y. Hort, H. Ball, G. Hayes, J. Shine, L. Selbie (1992)
Cloned human neuropeptide Y receptor couples to two different second messenger systems.Proceedings of the National Academy of Sciences of the United States of America, 89 13
S. Avvakumova, E. Galbiati, L. Sironi, S. Locarno, L. Gambini, C. Macchi, L. Pandolfi, M. Ruscica, P. Magni, M. Collini, M. Colombo, F. Corsi, G. Chirico, S. Romeo, D. Prosperi (2016)
Theranostic Nanocages for Imaging and Photothermal Therapy of Prostate Cancer Cells by Active Targeting of Neuropeptide-Y Receptor.Bioconjugate chemistry, 27 12
H. Snyder, A. Reedy, W. Lennarz (1958)
Synthesis of Aromatic Boronic Acids. Aldehydo Boronic Acids and a Boronic Acid Analog of Tyrosine1Journal of the American Chemical Society, 80
(2008)
World Health Organization, The global burden of disease: 2004 update, WHO
Specifically addressing cell surface molecules on cancer cells facilitates targeted cancer therapies that offer the potential to selectively destroy malignant cells, while sparing healthy tissue. Thus, undesired side‐effects in tumor patients are highly reduced. Peptide‐binding receptors are frequently overexpressed on cancer cells and therefore promising targets for selective tumor therapy. In this review, peptide‐binding receptors for anti‐cancer drug delivery are summarized with a focus on peptide ligands as delivery agents. In the first part, some of the most studied peptide‐binding receptors are presented, and the ghrelin receptor and the Y1 receptor are introduced as more recent targets for cancer therapy. Furthermore, nonpeptidic small molecules for receptor targeting on cancer cells are outlined. In the second part, peptide conjugates for the delivery of therapeutic cargos in cancer therapy are described. The essential properties of receptor‐targeting peptides are specified, and recent developments in the fields of classical peptide‐drug conjugates with toxic agents, radiolabeled peptides for radionuclide therapy, and boronated peptides for boron neutron capture therapy are presented.
Peptide Science – Wiley
Published: May 1, 2020
Keywords: ; ; ; ;
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.